Clinical Insights and Strategies to Improve NSCLC Care

Explore key issues in the management of advanced NSCLC in this educational program designed to keep you abreast of rapidly evolving treatment practices. Gain expert insights on new developments as they emerge with CME/CE-certified interactive modules, short expert commentaries, and an Interactive Decision Support Tool that will let you compare your treatment choices for specific patient scenarios in advanced NSCLC with those of 5 experts.
Lyudmila Bazhenova, MD
David R. Gandara, MD
Edward B. Garon, MD, MS
Matthew Gubens, MD, MS
Leora Horn, MD, MSc, FRCPC
Melissa L. Johnson, MD
Karen L. Reckamp, MD, MS
Thomas Stinchcombe, MD
Heather Wakelee, MD
H. Jack West, MD

ClinicalThought

What advances coming in 2018 have the most potential to affect the care of our patients with advanced NSCLC? H. Jack West, MD, offers his thoughts.

H. Jack West, MD Released: December 28, 2017

What is the best approach for our patients with progressive ALK-positive NSCLC? Here I share my thoughts based on the latest available evidence on using ALK inhibitors in the setting of progressive disease.

Lyudmila Bazhenova, MD Released: January 22, 2018

How will the new dosing schedule for nivolumab in NSCLC affect our current practice? Here are my thoughts.

Edward B. Garon, MD, MS Released: April 16, 2018

The optimal treatment of newly diagnosed patients with advanced NSCLC is changing. Here is how new findings reported at AACR 2018 are affecting my clinical practice.

Matthew Gubens, MD, MS Released: June 1, 2018

With checkpoint inhibitors now moving into both unresectable stage III and first-line metastatic NSCLC, how should we approach managing patients who progress on these agents in earlier disease settings? Read my thoughts on these new clinical challenges.

Edward B. Garon, MD, MS Released: July 26, 2018

How do the latest reported findings from ALTA-1L affect our decisions in first-line ALK-positive NSCLC?

Matthew Gubens, MD, MS Released: October 24, 2018

On-Demand Videos

Leora Horn, MD, MSc, FRCPC, provides insight on the optimal treatment of patients with advanced NSCLC and both an oncogenic driver mutation and high PD-L1 tumor expression.

Leora Horn, MD, MSc, FRCPC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Released: May 29, 2018 Expiration: May 28, 2019

Leora Horn, MD, MSc, FRCPC, provides insight on the optimal management of patients with progressive advanced squamous NSCLC with unknown PD-L1 expression.

Leora Horn, MD, MSc, FRCPC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.1 Nursing contact hours Released: June 4, 2018 Expiration: June 3, 2019

Gain expert insight on recent data informing the optimal treatment of patients with metastatic lung adenocarcinoma and no detectable tumor PD-L1 expression.

H. Jack West, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.4 Nursing contact hours Released: August 7, 2018 Expiration: August 6, 2019

Watch this on-demand video for expert perspective on how to apply the latest clinical data to treating patients with metastatic squamous NSCLC and low tumor PD-L1 expression.

H. Jack West, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.4 Nursing contact hours Released: August 21, 2018 Expiration: August 20, 2019

PDF

Download this simple resource providing an overall summary of advanced NSCLC care including an up-to-date treatment algorithm, toxicity management, and a listing of key enrolling clinical trials.

Thomas Stinchcombe, MD Released: February 15, 2018

Interactive Virtual Presentation

In this Virtual Presentation, Melissa L. Johnson, MD, discusses current expert treatment recommendations for 3 key patient scenarios in the rapidly evolving therapeutic landscape of advanced NSCLC. Afterwards, download the slides and use the treatment decision tool for your practice.

Melissa L. Johnson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: June 8, 2018 Expiration: June 7, 2019

In this downloadable slideset, Melissa L. Johnson, MD, presents recent practice changing data that impacts the management of patients with advanced NSCLC. Click here to use our online tool to see how to select optimal therapy for your patients.

Melissa L. Johnson, MD Released: June 8, 2018

Module-Metastatic NSCLC

Get expert insights on how the latest clinical data inform management of challenging NSCLC cases, including with intermediate PD-L1 expression, high PD-L1 levels and a BRAF V600E mutation, EGFR-mutated disease progressing on erlotinib, and metastatic disease with undetectable PD-L1 progressing on chemotherapy plus pembrolizumab.

Leora Horn, MD, MSc, FRCPC Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: November 12, 2018 Expiration: November 11, 2019

In this downloadable slideset, see expert recommendations for challenging lung cancer case scenarios and the evidence for those recommendations. Click here to use our updated online tool to see how to select optimal therapy for your patients with lung cancer.

Leora Horn, MD, MSc, FRCPC Released: November 12, 2018

Module-Stage III NSCLC

Examine evolving best treatment practices and recent clinical trial findings on immunotherapy approaches for unresectable stage III NSCLC, with expert commentary and interactive cases.

Karen L. Reckamp, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: October 31, 2018 Expiration: October 30, 2019

Examine recent clinical trial data on checkpoint inhibitors for unresectable stage III NSCLC in this expert-authored downloadable slideset.

Karen L. Reckamp, MD, MS Released: October 31, 2018

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with unresectable stage III or metastatic non-small-cell lung cancer with 5 world-renowned experts.

David R. Gandara, MD Melissa L. Johnson, MD Suresh S. Ramalingam, MD Heather Wakelee, MD H. Jack West, MD Released: October 29, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Celgene Corporation
Genentech
Lilly
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?